Literature DB >> 19494114

Tumor suppressor density-enhanced phosphatase-1 (DEP-1) inhibits the RAS pathway by direct dephosphorylation of ERK1/2 kinases.

Francesca Sacco1, Michele Tinti, Anita Palma, Emanuela Ferrari, Aurelio P Nardozza, Rob Hooft van Huijsduijnen, Takamune Takahashi, Luisa Castagnoli, Gianni Cesareni.   

Abstract

Density-enhanced phosphatase-1 (DEP-1) is a trans-membrane receptor protein-tyrosine phosphatase that plays a recognized prominent role as a tumor suppressor. However, the mechanistic details underlying its function are poorly understood because its primary physiological substrate(s) have not been firmly established. To shed light on the mechanisms underlying the anti-proliferative role of this phosphatase, we set out to identify new DEP-1 substrates by a novel approach based on screening of high density peptide arrays. The results of the array experiment were combined with a bioinformatics filter to identify eight potential DEP-1 targets among the proteins annotated in the MAPK pathway. In this study we show that one of these potential targets, the ERK1/2, is indeed a direct DEP-1 substrate in vivo. Pulldown and in vitro dephosphorylation assays confirmed our prediction and demonstrated an overall specificity of DEP-1 in targeting the phosphorylated tyrosine 204 of ERK1/2. After epidermal growth factor stimulation, the phosphorylation of the activation loop of ERK1/2 can be modulated by changing the concentration of DEP-1, without affecting the activity of the upstream kinase MEK. In addition, we show that DEP-1 contains a KIM-like motif to recruit ERK1/2 proteins by a docking mechanism mediated by the common docking domain in ERK1/2. ERK proteins that are mutated in the conserved docking domain become insensitive to DEP-1 de-phosphorylation. Overall this study provides novel insights into the anti-proliferative role of this phosphatase and proposes a new mechanism that may also be relevant for the regulation of density-dependent growth inhibition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19494114      PMCID: PMC2755929          DOI: 10.1074/jbc.M109.002758

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  Differential interaction of the tyrosine phosphatases PTP-SL, STEP and HePTP with the mitogen-activated protein kinases ERK1/2 and p38alpha is determined by a kinase specificity sequence and influenced by reducing agents.

Authors:  Juan José Muñoz; Céline Tárrega; Carmen Blanco-Aparicio; Rafael Pulido
Journal:  Biochem J       Date:  2003-05-15       Impact factor: 3.857

2.  A bipartite mechanism for ERK2 recognition by its cognate regulators and substrates.

Authors:  Jialin Zhang; Bo Zhou; Chao-feng Zheng; Zhong-yin Zhang
Journal:  J Biol Chem       Date:  2003-05-16       Impact factor: 5.157

Review 3.  The KEGG database.

Authors:  Minoru Kanehisa
Journal:  Novartis Found Symp       Date:  2002

4.  Identification of novel point mutations in ERK2 that selectively disrupt binding to MEK1.

Authors:  Fred L Robinson; Angelique W Whitehurst; Malavika Raman; Melanie H Cobb
Journal:  J Biol Chem       Date:  2002-01-31       Impact factor: 5.157

5.  Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1.

Authors:  Helena L Palka; Morag Park; Nicholas K Tonks
Journal:  J Biol Chem       Date:  2002-12-09       Impact factor: 5.157

6.  The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn).

Authors:  Leslie J Holsinger; Kevin Ward; Bill Duffield; Joseph Zachwieja; Bahija Jallal
Journal:  Oncogene       Date:  2002-10-10       Impact factor: 9.867

7.  A mutant receptor tyrosine phosphatase, CD148, causes defects in vascular development.

Authors:  Takamune Takahashi; Keiko Takahashi; Patricia L St John; Paul A Fleming; Takuya Tomemori; Toshio Watanabe; Dale R Abrahamson; Christopher J Drake; Takuji Shirasawa; Thomas O Daniel
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

8.  Direct integrin alphavbeta6-ERK binding: implications for tumour growth.

Authors:  Nuzhat Ahmed; Jun Niu; Douglas J Dorahy; Xinhua Gu; Sarah Andrews; Cliff J Meldrum; Rodney J Scott; Mark S Baker; Ian G Macreadie; Michael V Agrez
Journal:  Oncogene       Date:  2002-02-21       Impact factor: 9.867

9.  The protein-tyrosine phosphatase DEP-1 modulates growth factor-stimulated cell migration and cell-matrix adhesion.

Authors:  Enrico Jandt; Karsten Denner; Marina Kovalenko; Arne Ostman; Frank-D Böhmer
Journal:  Oncogene       Date:  2003-07-03       Impact factor: 9.867

10.  The specificity of extracellular signal-regulated kinase 2 dephosphorylation by protein phosphatases.

Authors:  Bo Zhou; Zhi-Xin Wang; Yu Zhao; David L Brautigan; Zhong-Yin Zhang
Journal:  J Biol Chem       Date:  2002-06-24       Impact factor: 5.157

View more
  36 in total

1.  Thrombospondin-1 acts as a ligand for CD148 tyrosine phosphatase.

Authors:  Keiko Takahashi; Raymond L Mernaugh; David B Friedman; Rebecca Weller; Nobuo Tsuboi; Hironobu Yamashita; Vito Quaranta; Takamune Takahashi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

2.  Agonistic anti-CD148 monoclonal antibody attenuates diabetic nephropathy in mice.

Authors:  Keiko Takahashi; Rachel H Kim; Lejla Pasic; Lilly He; Shinya Nagasaka; Daisuke Katagiri; Tracy May; Akira Shimizu; Raymond C Harris; Raymond L Mernaugh; Takamune Takahashi
Journal:  Am J Physiol Renal Physiol       Date:  2020-01-27

Review 3.  Deciphering enzyme function using peptide arrays.

Authors:  Alexandra Thiele; Gabriele I Stangl; Mike Schutkowski
Journal:  Mol Biotechnol       Date:  2011-11       Impact factor: 2.695

4.  Receptor type protein tyrosine phosphatases (RPTPs) - roles in signal transduction and human disease.

Authors:  Yiru Xu; Gary J Fisher
Journal:  J Cell Commun Signal       Date:  2012-08-01       Impact factor: 5.782

Review 5.  Inside the human cancer tyrosine phosphatome.

Authors:  Sofi G Julien; Nadia Dubé; Serge Hardy; Michel L Tremblay
Journal:  Nat Rev Cancer       Date:  2011-01       Impact factor: 60.716

6.  Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling.

Authors:  Deepika Arora; Sabine Stopp; Sylvia-Annette Böhmer; Julia Schons; Rinesh Godfrey; Kristina Masson; Elena Razumovskaya; Lars Rönnstrand; Simone Tänzer; Reinhard Bauer; Frank-D Böhmer; Jörg P Müller
Journal:  J Biol Chem       Date:  2011-01-24       Impact factor: 5.157

7.  Low density lipoprotein receptor-related protein 1 (LRP1) forms a signaling complex with platelet-derived growth factor receptor-beta in endosomes and regulates activation of the MAPK pathway.

Authors:  Selen Catania Muratoglu; Irina Mikhailenko; Christopher Newton; Mary Migliorini; Dudley K Strickland
Journal:  J Biol Chem       Date:  2010-03-10       Impact factor: 5.157

8.  An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis.

Authors:  Gabi Tarcic; Shlomit K Boguslavsky; Jean Wakim; Tai Kiuchi; Angela Liu; Felicia Reinitz; David Nathanson; Takamune Takahashi; Paul S Mischel; Tony Ng; Yosef Yarden
Journal:  Curr Biol       Date:  2009-11-17       Impact factor: 10.834

9.  Genome remodelling in a basal-like breast cancer metastasis and xenograft.

Authors:  Li Ding; Matthew J Ellis; Shunqiang Li; David E Larson; Ken Chen; John W Wallis; Christopher C Harris; Michael D McLellan; Robert S Fulton; Lucinda L Fulton; Rachel M Abbott; Jeremy Hoog; David J Dooling; Daniel C Koboldt; Heather Schmidt; Joelle Kalicki; Qunyuan Zhang; Lei Chen; Ling Lin; Michael C Wendl; Joshua F McMichael; Vincent J Magrini; Lisa Cook; Sean D McGrath; Tammi L Vickery; Elizabeth Appelbaum; Katherine Deschryver; Sherri Davies; Therese Guintoli; Li Lin; Robert Crowder; Yu Tao; Jacqueline E Snider; Scott M Smith; Adam F Dukes; Gabriel E Sanderson; Craig S Pohl; Kim D Delehaunty; Catrina C Fronick; Kimberley A Pape; Jerry S Reed; Jody S Robinson; Jennifer S Hodges; William Schierding; Nathan D Dees; Dong Shen; Devin P Locke; Madeline E Wiechert; James M Eldred; Josh B Peck; Benjamin J Oberkfell; Justin T Lolofie; Feiyu Du; Amy E Hawkins; Michelle D O'Laughlin; Kelly E Bernard; Mark Cunningham; Glendoria Elliott; Mark D Mason; Dominic M Thompson; Jennifer L Ivanovich; Paul J Goodfellow; Charles M Perou; George M Weinstock; Rebecca Aft; Mark Watson; Timothy J Ley; Richard K Wilson; Elaine R Mardis
Journal:  Nature       Date:  2010-04-15       Impact factor: 49.962

10.  Phosphatome profiling reveals PTPN2, PTPRJ and PTEN as potent negative regulators of PKB/Akt activation in Ras-mutated cancer cells.

Authors:  Jasminka Omerovic; Michael J Clague; Ian A Prior
Journal:  Biochem J       Date:  2010-01-27       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.